← back to search

Scott B. Ficarro

Harvard University · US
Area of research
Spectroscopy · Molecular Biology
Research interest
Research interests include Advanced Proteomics Techniques and Applications, Mass Spectrometry Techniques and Applications, Protein Degradation and Inhibitors, and Lung Cancer Treatments and Mutations.
h-index
69
citations
16,442
works
237
NIH funding
primary concept
Chemistry
email

Recent publications

Structural basis for the recruitment and selective phosphorylation of Akt by mTORC2.
2026cited by 1position: contributordoi
Structural basis for the recruitment and selective phosphorylation of Akt by mTORC2
Science 2025cited by 5position: middledoi
Template-assisted covalent modification underlies activity of covalent molecular glues
Nature Chemical Biology 2024cited by 83position: middledoi
APIR: Aggregating Universal Proteomics Database Search Algorithms for Peptide Identification with FDR Control.
2024cited by 2position: contributordoi
Leveraging HILIC/ERLIC Separations for Online Nanoscale LC-MS/MS Analysis of Phosphopeptide Isoforms from RNA Polymerase II C-terminal Domain
2024cited by 1position: contributordoi
Open-source electrophilic fragment screening platform to identify chemical starting points for UCHL1 covalent inhibitors
SLAS Discovery 2024cited by 0position: contributordoi
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Nature 2023cited by 101position: middledoi
Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2–dependent glutaminolysis pathway
Science Advances 2022cited by 35position: middledoi
Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway.
2022cited by 28position: contributordoi
Translocation of polyubiquitinated protein substrates by the hexameric Cdc48 ATPase
Molecular Cell 2021cited by 79position: middledoi
APIR: Aggregating Universal Proteomics Database Search Algorithms for Peptide Identification with FDR Control
2021cited by 0position: contributordoi
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
Cancer Cell 2020cited by 467position: middledoi
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism
Scientific Reports 2020cited by 121position: middledoi
Discovery and Structure–Activity Relationship Study of ( <i>Z</i> )-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors
Journal of Medicinal Chemistry 2020cited by 29position: middledoi
Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes
Nature 2019cited by 330position: middledoi
Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin unfolding
Science 2019cited by 307position: middledoi
Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin unfolding.
2019cited by 258position: contributordoi
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype
Cell chemical biology 2019cited by 163position: middledoi
Akt Kinase Activation Mechanisms Revealed Using Protein Semisynthesis
Cell 2018cited by 151position: middledoi
SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform
Cell chemical biology 2018cited by 128position: middledoi
A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification
Journal of the American Chemical Society 2018cited by 92position: middledoi
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia
Cancer Discovery 2018cited by 82position: middledoi
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
Cell chemical biology 2017cited by 137position: middledoi
Hepatic Dysfunction Caused by Consumption of a High-Fat Diet
Cell Reports 2017cited by 109position: middledoi
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
eLife 2017cited by 42position: middledoi
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Nature Chemical Biology 2016cited by 368position: middledoi
LIN28 Regulates Stem Cell Metabolism and Conversion to Primed Pluripotency
Cell stem cell 2016cited by 353position: middledoi
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Nature 2014cited by 895position: middledoi
In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C
Proceedings of the National Academy of Sciences 2014cited by 244position: middledoi
Alternative Splicing of MBD2 Supports Self-Renewal in Human Pluripotent Stem Cells
Cell stem cell 2014cited by 116position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jarrod A. Marto · Harvard University23 papers (2012–2023)Nathanael S. Gray · Stanford University11 papers (2012–2020)Tinghu Zhang · Stanford University7 papers (2012–2020) · 6 papers (2019–2024)Jarrod A. Marto · Target (United States)6 papers (2019–2024)Kenneth D. Westover · The University of Texas Southwestern Medical Center4 papers (2013–2019)Taebo Sim · Severance Hospital4 papers (2012–2019)Nicholas Kwiatkowski · Woomera Therapeutics4 papers (2014–2019)Ting Xie · Guangzhou University of Chinese Medicine3 papers (2012–2014) · 3 papers (2014–2020)John R. Engen · Northeastern University3 papers (2013–2021)Zhejian Ji · Westlake University2 papers (2019–2021)Tom A. Rapoport · Howard Hughes Medical Institute2 papers (2019–2021)Hwan Geun Choi · Biocon (Switzerland)2 papers (2013–2014)Lianbo Li · The University of Texas Southwestern Medical Center2 papers (2017–2019)Richard A. Young · Whitehead Institute for Biomedical Research2 papers (2014–2016)Yiling Chen · Harvard University2 papers (2021–2024)MeiLu McDermott · University of Southern California2 papers (2021–2024)Kyla Woyshner · Johns Hopkins University2 papers (2021–2024) · 2 papers (2021–2024)